Home » T2Candida Antimicrobial Stewardship Implications
T2Candida Antimicrobial Stewardship Implications
The T2Candida® Panel, paired with antifungal stewardship has been shown to provide guidance and improvements in the timeliness and overall use of antifungals, aid antifungal stewardship initiatives and show significant hospital savings in patients with candidemia. Identification of patients with or without candidemia within 3-5 hours using the T2Candida Panel has the potential to significantly improve patient outcomes and overall hospital expenditure.
Download the white paper for a summary of current published data on antifungal stewardship with the use of the T2Candida Panel.
Please enter your email for instant access to the white paper.
T2 Biosystems, an emerging leader in the field of in vitro diagnostics, is dedicated to saving lives and reducing the cost of healthcare by empowering clinicians to effectively treat patients faster than ever before. T2 Biosystems is focused on addressing critical unmet needs in healthcare starting with sepsis, one of the deadliest and most expensive conditions in hospitals today.
The T2Dx Instrument, the T2Bacteria and T2Candida Panels have received marketing authorization from the U.S. Food and Drug Administration. All other T2 Biosystems products are considered investigational and for research use only.
T2 Biosystems®, T2MR®, T2Bacteria®, T2Candida®, and T2Dx® are registered trademarks of T2 Biosystems, Inc. “T2Biosystems” and the T2 Biosystems, Inc. logo design are registered trademarks or trademarks of T2Biosystems, Inc. All software and documentation is subject to T2 Biosystems, Inc. copyrights. All rights reserved. T2Direct Diagnostics™, T2HemoStat™, T2Plex™, T2Cauris™, T2Resistance™ and T2SARS-CoV-2™ are trademarks of T2 Biosystems, Inc.